ARBUTUS BIOPHARMA CORP's ticker is ABUS and the CUSIP is 03879J100. A total of 91 filers reported holding ARBUTUS BIOPHARMA CORP in Q2 2021. The put-call ratio across all filers is 1.48 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $126,453 | -8.5% | 62,292 | +3.7% | 0.00% | 0.0% |
| Q2 2023 | $138,179 | -16.8% | 60,078 | +9.6% | 0.00% | 0.0% |
| Q1 2023 | $166,141 | +32.7% | 54,832 | +2.0% | 0.00% | 0.0% |
| Q4 2022 | $125,217 | +27.8% | 53,741 | +4.8% | 0.00% | 0.0% |
| Q3 2022 | $98,000 | -28.5% | 51,269 | +1.4% | 0.00% | 0.0% |
| Q2 2022 | $137,000 | +1.5% | 50,544 | +11.7% | 0.00% | 0.0% |
| Q1 2022 | $135,000 | -18.7% | 45,232 | +5.9% | 0.00% | 0.0% |
| Q4 2021 | $166,000 | -12.2% | 42,699 | -2.9% | 0.00% | 0.0% |
| Q3 2021 | $189,000 | +42.1% | 43,977 | +0.5% | 0.00% | – |
| Q2 2021 | $133,000 | +64.2% | 43,763 | +94.4% | 0.00% | – |
| Q1 2019 | $81,000 | -9.0% | 22,516 | -3.1% | 0.00% | – |
| Q4 2018 | $89,000 | -59.7% | 23,245 | -0.8% | 0.00% | -100.0% |
| Q3 2018 | $221,000 | +31.5% | 23,425 | +1.8% | 0.00% | 0.0% |
| Q2 2018 | $168,000 | – | 23,002 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| JACOB ASSET MANAGEMENT OF NEW YORK LLC | 340,000 | $1,459,000 | 0.53% |
| RTW INVESTMENTS, LP | 4,733,323 | $20,306,000 | 0.31% |
| APIS CAPITAL ADVISORS, LLC | 70,000 | $300,000 | 0.29% |
| Hudson Bay Capital Management LP | 1,800,000 | $7,722,000 | 0.10% |
| COWEN AND COMPANY, LLC | 249,215 | $1,069,000 | 0.05% |
| Kerrisdale Advisers, LLC | 100,000 | $429,000 | 0.05% |
| Woodline Partners LP | 496,172 | $2,129,000 | 0.04% |
| Shay Capital LLC | 60,000 | $257,000 | 0.03% |
| Walleye Capital LLC | 231,037 | $991,000 | 0.03% |
| BOOTHBAY FUND MANAGEMENT, LLC | 212,700 | $912,000 | 0.02% |